Chapter 81: Primary Care of the Patient With Cancer

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a patient survives like a grueling, years -long battle with cancer.

Yeah, which is incredible in itself.

Exactly.

Only to die of preventable heart failure a decade later, simply because their primary care provider was, well, too afraid to prescribe a standard statin.

I know.

It sounds completely backwards.

It really does.

But statistically, I mean, it happens every single day.

It does.

So welcome to the deep dive.

If you're an advanced practice nursing student listening right now, consider this your custom tailored one -on -one tutoring session.

Because millions of cancer survivors are about to enter your clinic.

Right.

And you are going to be the one managing their incredibly complex lifelong care.

It's a massive clinical shift.

You know, historically, we thought of cancer survivorship as something managed entirely by oncology.

Like the oncologist handles everything.

Exactly.

But the reality of modern medicine is that there are over 16 .9 million cancer survivors in the US today.

Wow.

And we're projected to hit 26 .1 million by 2040.

That is just a staggering volume of patients.

Right.

We simply do not have enough oncology services to handle that.

Why?

So the paradigm has completely shifted.

Primary care providers are now the anchor for these patients.

Which means you, the APN student, need to know this stuff inside and out.

Exactly.

So today, our mission is to comprehensively map out the clinical reasoning, the path of physiology, and the evidence -based management plans you need to safely guide these patients.

And to make sure you're fully prepped for your exams, obviously.

Obviously.

Okay.

Let's unpack this.

We have to start exactly where survivorship actually begins, which is the moment of diagnosis.

Right.

This initial period through the completion of active treatment is known as the acute phase.

Now, obviously, the oncologists are the ones driving the heavy hitting chemotherapy and radiation protocols right now.

Yeah.

They're running the show on the acute treatment.

But as the primary care provider, your role doesn't just disappear.

You are managing their baseline health maintenance, assessing functional status, and handling the foundational symptom management.

Exactly.

And there's a massive, I mean, an incredibly urgent priority setting issue that falls right into your lap during this acute phase.

Oh, right.

Fertility.

Yes.

Fertility preservation.

When a young adult is diagnosed with cancer, the oncology team is often in an absolute rush to start life -saving treatment.

Right.

The house is on fire, so to and they just want to put it out.

Because of that urgency, discussions about banking sperm or, you know, freezing eggs, frequently get completely overlooked.

And once the chemo starts, it's often too late.

Precisely.

Yeah.

You have to understand the pathophysiology of what these drugs do.

Like, alkylating agents and gonadal radiation, they don't just temporarily pause reproductive capability.

They wipe it out.

Yeah.

They cause profound, often irreversible damage to germ cell function and sperm or egg production.

So as the PCP, you need to be the one to step back and look at the whole patient's life trajectory.

Right.

You initiate this discussion before any treatment begins.

It is a critical scope of practice consideration.

That is a major clinical takeaway.

You have to be proactive, not reactive.

Absolutely.

Now, as the patient moves through this acute phase of treatment, the most pervasive symptom, though, report to you isn't necessarily nausea or pain.

No, it's cancer -related fatigue.

Right.

It is the most common and persistent side effect across all modalities.

Doesn't matter if they're getting surgery, chemo, radiation, immunotherapy, they are exhausted.

It is an absolute overwhelming exhaustion.

And what makes it so difficult to manage is that it's fundamentally compounded by, well, the inactivity, the depression, and the disrupted sleep that comes with the cancer experience.

But this is where current clinical guidelines present something that sounds completely counterintuitive.

Oh yeah, this always trips students up.

The overwhelmingly supported evidence -based intervention for this profound fatigue is exercise.

Now, wait a minute.

If a patient's body is utterly exhausted from cellular damage and harsh chemotherapy, and we're telling them to go exercise.

I know.

It feels like telling someone with a flat tire to just drive faster.

I completely understand why it sounds wild at first glance.

But what's fascinating here is the underlying physiological mechanism.

Okay.

Break that down for us.

You have to look at what happens when a patient becomes highly sedentary during treatment.

Increased sedentary behavior causes a massive rapid decline in functional ability and cardiopulmonary strength.

Oh, okay.

So the fatigue they're feeling isn't exclusively from the cytotoxicity of the drugs.

A huge portion of it is from rapid profound deconditioning.

Oh, so to use a different analogy, think of the body's cardiovascular system like a

rechargeable battery that's rapidly losing its maximum charge capacity.

If you just leave it unplugged on the shelf, meaning total bed rest, the battery degrades even faster.

Exactly.

So exercise isn't draining the battery.

It's actively recalibrating the maximum charge.

You aren't ignoring their exhaustion.

You're treating the physiological deconditioning that makes the exponentially worse.

That is a perfect way to conceptualize it.

Exercise is the only intervention proven to break that vicious cycle of fatigue, muscle wasting, and, you know, the subsequent depression.

So by safely maintaining their functional baseline, you ensure they can actually tolerate the remainder of their oncology treatments.

Precisely.

So the active treatment eventually ends.

The cancer is technically gone, or at least in remission, but the physiological aftermath has really just begun.

Yeah, that's when things shift.

Which brings us into the long -term effects phase.

This typically covers that first one to two years of recovery.

The acute issues like the hair loss and mouth sores generally resolve, but this is where lingering insidious toxicities emerge.

And the oncology follow -ups drop to maybe once every few months.

Right, putting the primary care provider squarely in the driver's seat.

And one of the most debilitating issues you'll assess for is chemotherapy -induced peripheral neuropathy, or CIPN.

You will see this incredibly often.

Especially with neurotoxic drugs like oxaloplatin and paclotaxil.

The functional impact of CIPN cannot be overstated.

We're talking about severe tingling, numbness, shooting pains in the extremities.

Yeah, the sensory loss can get so profound that a patient literally cannot feel their fingers enough to button their own shirt.

And more importantly, they lose proprioception in their feet, which severely compromises their balance.

Which makes them a massive fall risk.

Exactly.

Which dictates your pharmacologic management plan.

There's currently no cure for CIPN.

Right.

The nerve damage often becomes a lifelong challenge.

So your role is twofold.

Managing the neuropathic pain with agents like gabapentin or pregabalin, and aggressively implementing fall precautions and physical therapy referrals.

But while you're managing that neuropathy, there's another major red flag finding you need to aggressively screen for during this one to two year window.

Oh, the thyroid trap.

Yes, thyroid dysfunction.

This is such a critical differential diagnosis trap for a new practitioner.

Imagine a patient who is 18 months post -treatment and they come into your clinic reporting profound,

unshakable fatigue.

It is so easy to fall into the trap of assuming, well, they had cancer.

So this is just lingering cancer -related fatigue.

Right.

You just write it off.

Exactly.

But you must remember that radiation to the head, neck, or upper chest, as well as modern systemic immunotherapies, can completely obliterate normal thyroid function.

Wait,

immunotherapies too?

Oh yeah.

Immunotherapies work by taking the brakes off the immune system to fight cancer.

But that hyperactive immune system often attacks the patient's own thyroid gland.

Ah, causing autoimmune thyroiditis.

You got it.

So if you don't actively screen their TSH and free T4, you might miss a highly treatable endocrine issue.

Always look for the treatable underlying physiological cause before chalking a symptom up to the generalized cancer experience.

Now, as you manage these survivors, part of your surveillance toolkit will involve tumor markers.

Right.

Let's look at table 81 .2.

It is crucial for students to understand how to apply these guidelines correctly.

You have to shift your mindset.

Okay, how so?

Do not think of tumor markers as initial diagnostic tools used to find a brand new cancer in a healthy person.

They are recurrence monitoring tools.

Right, because if you run them on the general population, you'll just get a nightmare of false positives.

Exactly.

But for a patient with a known history, they're invaluable.

We need to drill a few specific markers that you will absolutely see on your exams and in your clinics.

Let's start with carcinoembryonic antigen, or CEA.

So CEA is a glycoprotein normally found in fetal tissue.

If it starts elevating in an adult survivor, it's a major red flag from eukosal tumors.

Like which ones?

You monitor this specifically for patients with a history of colon, pancreatic, lung, and breast cancers.

Got it.

Next is CA125.

This is a protein shed into the bloodstream by certain types of cells, predominantly monitored for ovarian, endometrial, and fallopian tube cancers.

Then there's prostate -specific antigen, or PSA, which is obviously for prostate cancer surveillance.

And finally, alpha -fetoprotein, or AFP.

AFP is another fetal protein.

In the adult survivorship context, an abnormal elevation is a key surveillance marker for liver and testicular cancers.

Okay, so you just draw the lab and if it's high, you panic.

No, no.

The critical clinical reasoning here is to look for trends over time through serial monitoring.

You don't necessarily panic over a singular, slightly off lab draw.

You're watching the trajectory of the marker to catch a recurrence before it becomes symptomatic.

Okay, so once we look past that two -year mark, we enter the realm of late effects.

These are the physical changes that emerge insidiously over decades.

And this is perhaps the darkest irony of oncology, right?

Yeah, it really is.

The exact same treatment that their first cancer can actually mutate their DNA enough to cause a second, entirely new malignancy down the road.

It's a harsh reality, but one you must diligently monitor for.

The pathophysiology and the latency timeline of these second cancers are directly tied to the type of initial treatment.

So, chemo versus radiation.

Exactly.

Chemotherapy, particularly alkylating agents into

inhibitors, causes profound systemic DNA damage.

The secondary leukemias that result from this damage typically have a shorter latency period.

Meaning they show up sooner.

Right, usually period two to five years post -treatment.

But radiation therapies have a completely different timeline.

Yes.

Radiation -induced solid tumors like, say, a breast cancer developing after chest radiation for a childhood Hodgkin's lymphoma, those have a much longer latency.

Because it takes time for solid mass to grow.

Exactly.

Because it takes time for those localized irradiated cells to mutate and grow into a mass.

You typically won't see those solid tumors until at least five to ten plus years after treatment.

Okay, here's where it gets really interesting.

And by interesting, I mean incredibly urgent for you as a primary care provider.

Let's talk about cardiovascular safety.

This is huge.

Statistically, cardiovascular mortality is two to six times higher in cancer survivors compared to the general public.

And if they were diagnosed with cancer before age 55, they have a snagging tenfold higher risk of cardiovascular mortality.

Because the heart takes a massive multifaceted hit from both the inflammatory burden of the disease itself and the cytotoxicity of the treatments.

It's double mammy.

To manage this safely, you have to understand the pharmacological distinction between two very common cancer drugs, doxorubicin and trastuzumab.

Okay, let's break the mechanisms down because they are totally different.

Doxorubicin is an anthracycline chemotherapy.

Its mechanism generates free radicals that myocardial cells simply cannot detoxify.

So the cells just die.

Yes.

This causes permanent irreversible cardiac cellular death.

The damage is cumulative and dose dependent.

Meaning the late effects like severe cardiomyopathy and refractory heart failure can silently develop and suddenly present decades after the chemotherapy has ended.

Exactly.

Trastuzumab, on the other hand, is a targeted therapy often used in breast cancer.

It blocks HER2 receptors on the heart cells, which causes cellular dysfunction and a drop in the ejection fraction.

But importantly, it doesn't necessarily kill the cell, right?

Right.

The heart function drops, but it is often reversible once the drug is stopped or managed.

But here is the massive gap in current primary care practice that we mentioned right at the

Why are primary care providers statistically underprescribing cardioprotective therapies to cancer survivors?

That's so frustrating.

The data shows that these survivors are prescribed statins, ACE inhibitors, and beta blockers, significantly less frequently than the general population.

That makes zero sense.

It is a recognized failure in the continuum of care.

Often providers get so hyper -focused on the patient's complex oncology history that they hesitate to introduce new medications.

Like they're afraid of drug interactions.

Fearing unknown interactions, yeah.

Or simply feeling overwhelmed by polypharmacy.

But by withholding standard evidence -based cardioprotective therapies, we are leaving them exposed to a highly preventable cause of death.

You, as the future APN, must correct this in your practice.

You have to aggressively manage their lipids and blood pressure with the exact same, if not more, rigor as your non -cancer patients.

Absolutely.

Do not let your cancer survivor die of a preventable heart attack.

Okay, now transitioning from the heart.

We have to look at the endocrine system, particularly in our pediatric survivors.

The hypothalamus and the pituitary gland are exquisitely sensitive to cranial radiation.

When you damage the hypothalamus, you disrupt the entire downstream regulatory system for metabolism, growth, and body composition.

And the clinical reality for pediatric patients is just shocking.

Nearly 66 % of cancer survivors eventually develop metabolic syndrome.

Picture your waiting room.

If you have three pediatric survivors sitting out there, statistically two of them are battling metabolic syndrome.

That completely changes how you look at a routine wellness check.

It means you are aggressively screening for insulin resistance,

central obesity,

atherogenic dyslipidemia, and hypertension at a much younger age than you normally would.

We also have to monitor the lungs and the neurological system.

Therapies involving the drug Bluomycin or radiation to the chest and mediastinum are strongly linked to severe pulmonary fibrosis and permanently reduced lung volumes.

And neurologically, you must actively assess their hearing.

Oh, right, otoxicity.

Yes.

Ototoxic therapies, specifically platinum -based chemotherapies like cisplatin, cause severe, irreversible hearing loss in almost 85 % of patients.

85 %?

Cranial radiation causes it in about 38%.

This isn't just a minor inconvenience.

Permanent high -frequency hearing loss profoundly affects their ability to work, socialize, and function safely in the world.

Which perfectly illustrates why your role is so vital.

You successfully monitor their heart risk, their neuropathy, their thyroid, but the reality is survivorship isn't just about cellular health and organ systems.

Bad at all.

The physical damage often acts as a catalyst for profound psychosocial trauma.

Advanced practice nursing requires treating the entire lived experience and the socioeconomic realities of the patient.

We really need to look at the hidden costs of survival.

Starting with chronic pain.

The prevalence of pain in this population is staggering.

Even 16 years after their initial diagnosis,

almost 35 % of survivors report experiencing chronic pain that limits their daily lives and their ability to maintain employment.

And if you connect this to the bigger picture, there is a glaring tragic socioeconomic disparity here.

Cancer pain is highly prevalent, but it is exceptionally poorly managed in Medicaid populations.

Because of the cost.

Right.

Because the patient simply cannot afford the co -pays for their multimodal medications.

You have to assess pain at every single visit, but you also have to understand the financial barriers to your pharmacologic management plans.

It doesn't matter how perfect your prescription is if they can't afford to pick it up at the pharmacy.

You also have to initiate sensitive discussions about reproductive and sexual health because the treatments just ravage the pelvic region and hormone levels.

Yeah.

Young females often face premature medically induced menopause from treatment.

Right.

And they're dealing with the profound emotional grief of losing their fertility, which is compounded by severe vasomotor symptoms, vaginal atrophy, and dryness.

For male survivors, erectile dysfunction is incredibly common, often due to nerve or vascular damage from pelvic radiation or prostate surgeries.

And you can absolutely prescribe PDE -5 inhibitors like sildenafil, but you need to manage their expectations.

Why is that?

Because the underlying nerve and vascular tissue has been physically traumatized, these medications can take a much longer time to become effective in post -cancer patients compared to the general population.

That's a great clinical pearl.

Then we have to address the mental health aspect.

There's a specific widely recognized phenomenon called fear of cancer recurrence.

It affects up to 70 % of breast cancer survivors and many others across different diagnoses.

The trauma is so deep that every single cough, every minor backache feels like a metastatic tumor.

They live in a constant state of hypervigilance.

And from a management perspective, this is critical for your clinical reasoning.

You cannot fix this with a standard anti -anxiety pill.

Benzodiazepines or SSRIs do not cure the fundamental existential fear of recurrence.

The evidence -based, non -pharmacologic intervention here is ACT.

Acceptance and Commitment Therapy.

Exactly.

ACT is a brilliant, skills -based psychological intervention.

It doesn't try to force the patient to simply stop worrying, which never works anyway.

Instead,

it uses mindfulness techniques to help survivors accept the intrusive thought, acknowledging, yes, I am afraid my cancer is back, without letting that fear dictate their behavior or consume their present moment.

It breaks the cognitive fusion between the thought and the panic.

You also have to assess their economic health, which brings up the concept of Joe Block.

Almost 20 % of survivors find themselves trapped in jobs they desperately want to leave, simply because they rely on their employer's specific health insurance network.

They cannot risk losing coverage or navigating a lapse in care with their complex medical history, so their entire career trajectory becomes frozen.

Which generates an incredible amount of chronic stress.

And speaking of stress, you must turn your attention to the caregiver in the room.

We can't forget the caregivers.

The caregiver is dealing with an unpaid, entirely untrained medical role.

They are navigating Byzantine insurance webs, coordinating multiple specialists, and quietly grieving the massive change in their own life circumstances.

You are officially treating the patient, but your interprofessional care plan must absolutely collaborate with and support the caregiver.

Okay, so knowing all these incredibly complex risks, the latent organ damage, the psychological toll, the socioeconomic barriers, how do you, the APN student, actually build proactive management plan?

We transition now to the PCP's role as the ultimate care coordinator, utilizing the four core pillars of health promotion.

Exercise, nutrition,

smoking cessation, and immunizations.

Let's look at the exact, evidence -based management plan for exercise, which comes straight from the American College of Sports Medicine, or ACSM, guidelines.

The exercise prescription.

Right.

The initial exercise prescription you should give a survivor starts with the minimum of three days a week.

That means 30 minutes per session of combined aerobic and resistance training.

And as they recover their baseline strength, you titrate that prescription up.

The ultimate physiological goal is 300 minutes of moderate aerobic exercise per week, plus at least two days dedicated to resistance training.

But importantly, you aren't just telling a vulnerable patient to go join a gym.

Right.

This is a highly interprofessional effort.

You assess their capability, advise them on the goals, and then refer them appropriately.

Yeah.

A patient with severe CIPN, or bone metastasis, needs to start with a referral to medically supervised physical therapy to prevent injury.

And as they progress and stabilize.

You transition them to community groups.

Programs like Livestrong at the YMCA are specifically designed for this population, and eventually they graduate to home -based, self -directed maintenance programs.

For their diet, the guidelines from the American Cancer Society are very clear.

Emphasize a robust plant -based diet, strictly limit red and processed meats, and minimize alcohol intake.

Because alcohol is a known carcinogen linked to several secondary cancers.

Exactly.

Smoking cessation is equally vital.

You can and should prescribe nicotine replacement therapies, or oral medications like varenicline and bupropion to assist them.

But here is a major safety consideration and a classic exam question.

Pay attention to this one.

Both varenicline and bupropion lower the seizure threshold and can exacerbate psychiatric conditions.

They are absolutely contraindicated in patients with a history of seizures or severe psychiatric illness.

You must thoroughly check their past medical history before writing that script.

Great safety catch.

Now what about dental care and infection precautions?

Patients who have undergone head or neck radiation suffer from profound destruction of their salivary glands.

The resulting loss of saliva removes the mouth's natural bacterial buffer.

Leading to rapid severe dental caries and deep periodontal disease.

Yes.

You must coordinate long -term aggressive oral health screenings with their dental team.

And regarding their overall immune function, do they ever get back to normal?

The good news is that most patients recover their baseline immune function within 6 to 12 months after standard chemotherapy ends.

But there is a massive clinical exception you have to memorize.

Okay.

What is it?

Patients treated with specific immunotherapeutics like rituximab, which intentionally targets and destroys B cells, or those who have had heavy systemic radiation or stem cell transplants, may develop profound lifelong immune deficiency.

Wow.

Lifelong.

Yeah.

They permanently lose much of their B cell function, which means they lose their ability to mount a robust vaccine response and remain at constant lifelong risk for severe bacterial and viral infections.

Which leads us perfectly to our final critical safety alert regarding vaccinations.

Routine vaccinations are generally encouraged for survivors to protect them, but you must absolutely avoid live virus vaccines in patients who are currently receiving active treatment or who have only recently completed it.

Because their immune system is deeply suppressed.

They cannot mount a defense against the live virus in the vaccine, and you could inadvertently trigger a massive overwhelming infection.

That means no nasal spray flu vaccine, no MMR, no varicella, and no live zoster virus vaccines until they are thoroughly cleared.

Exactly.

What does this all mean?

We've covered everything from irreversible cellular death and neuropathy to the mechanics of metabolic syndrome and the psychosocial trap of jaw block.

It means we are witnessing a monumental paradigm shift.

For decades, the medical establishment viewed cancer solely as an acute terminal threat that was fought entirely within the walls of a hospital.

But what this deep dive reveals is that the future of oncology is actually grounded right in the primary care clinic.

We have to start treating cancer survivorship not as a static cure, but as a lifelong complex chronic illness.

Manage with the exact same vigilance and proactive care as diabetes or heart failure.

We've talked so much today about managing the patient's physical and mental aftermath, but here is something provocative to mull over as you head into your clinical rotations.

Okay, let's hear it.

As cancer treatments become incredibly targeted, literally altering a patient's DNA,

and fundamentally reprogramming their immune systems to fight the disease, are we eventually going to see a future where primary care essentially becomes genetic maintenance?

Wow.

You aren't just managing standard symptoms anymore, you know.

You are managing modified human biology.

It is a fascinating frontier.

And to our advanced practice nursing student listening right now,

you are going to be the one on that frontier.

You are going to be the practitioner catching that subtle thyroid dysfunction, prescribing that life -saving cardioprotective statin, and building that interprofessional bridge to physical therapy.

You are the anchor these patients desperately need.

Thank you for letting us be part of your study routine today.

A warm thank you and sign off specifically from the Last Minute Lecture Team.

Keep crushing your clinicals, and we will see you on the next deep dive.